Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
STVN · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortStevanato Group S.p.A. is profitable, generates cash and carries moderate debt, with revenue growing (+7.4% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 16.8% | 73/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 11.8% | 67/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 9.7% | 48/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 7.1% | 47/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.76× | 80/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.39× | 89/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 2.25× | 50/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 8.77× | 69/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.00 | 74/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 1.9% | 28/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.16× | 0/100 |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 9.8% | 75/100 |
| Operating margin volatility | 2.1% | 90/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 6.4% | 52/100 |
|---|---|---|
| EPS growth, 3-year average | -1.9% | 16/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 844 | 984 | 1,085 | 1,104 | 1,186 |
| Cost of revenue | 579 | 664 | 745 | 802 | 842 |
| Gross profit | 265 | 320 | 340 | 302 | 344 |
| Research & development | 30 | 34 | 36 | 32 | 25 |
| Operating income | 162 | 192 | 201 | 161 | 199 |
| Interest expense | 19 | 30 | 18 | 14 | 23 |
| Pre-tax income | 166 | 188 | 190 | 160 | 189 |
| Income tax | 31 | 45 | 44 | 43 | 49 |
| Net income | 134 | 143 | 146 | 118 | 140 |
| Diluted EPS | €0.53 | €0.54 | €0.55 | €0.43 | €0.51 |
| Diluted shares (millions) | 253 | 265 | 265 | 271 | 273 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
4.00 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 4, 2026